441 results on '"Perl, Alexander"'
Search Results
2. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia
3. Evolving racial/ethnic disparities in AML survival in the novel therapy era
4. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
5. Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia
6. A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia
7. Approaching a therapeutic inflection point for FLT3-mutated AML
8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
9. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
10. Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
11. Menin Inhibition With Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
12. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
13. Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients
14. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
15. Which novel agents will have a clinically meaningful impact in AML at diagnosis?
16. A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia
17. Gilteritinib: potent targeting of FLT3 mutations in AML
18. Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
19. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
20. Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia
21. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
22. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
23. Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL
24. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
25. Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
26. Availability of FLT3 inhibitors: how do we use them?
27. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
28. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia
29. Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia
30. Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total Therapy
31. AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results
32. AML-029 Quizartinib Prolonged Overall Survival (OS) vs Placebo Plus Intensive Induction and Consolidation Therapy Followed by Single-Agent Continuation in Patients Aged 18-75 Years With Newly Diagnosed FLT3–Internal Tandem Duplication Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)
33. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
34. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
35. A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
36. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center
37. The role of targeted therapy in the management of patients with AML
38. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
39. Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
40. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
41. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers.
42. Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation
43. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
44. Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
45. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay
46. The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
47. Vitamin C deficiency in patients with acute myeloid leukemia: a case series and review of the literature
48. Testing the Perceived Ease of Use in Social Media : Acceptance Testing for People with Intellectual and Cognitive Disabilities
49. The most novel of the novel agents for acute myeloid leukemia
50. Crenolanib is a selective type I pan-FLT3 inhibitor
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.